| Target Validation Information | |||||
|---|---|---|---|---|---|
| Target ID | T58970 | ||||
| Target Name | Mitogen-activated protein kinase 1 | ||||
| Target Type | Clinical Trial |
||||
| Drug Potency against Target | FR-180204 | Drug Info | IC50 = 1900 nM | [527815] | |
| DEBROMOHYMENIALDISINE | Drug Info | IC50 = 824 nM | [527140] | ||
| Ro-4396686 | Drug Info | IC50 = 12600 nM | [528018] | ||
| References | |||||
| Ref 527815 | Bioorg Med Chem Lett. 2006 Jan 1;16(1):55-8. Epub 2005 Oct 18.Crystal structure of human ERK2 complexed with a pyrazolo[3,4-c]pyridazine derivative. | ||||
| Ref 527140 | Bioorg Med Chem Lett. 2004 Aug 16;14(16):4319-21.Potent inhibition of checkpoint kinase activity by a hymenialdisine-derived indoloazepine. | ||||
| Ref 528018 | Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3. Epub 2006 Feb 3.Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.